RECRUITING

HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

Talk to us

Conditions

Heart Failure (HF)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.

Official Title

HEMOTAG® Assessment for Short-term Outcomes of Heart Failure [HATS-OFF]

Quick Facts

Study Start:2022-01-31
Study Completion:2024-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04149743

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age greater than or equal to 22 years old.
  2. * An index hospital admission for ADHF presenting with symptoms, clinical signs, and chest x-ray (CXR) findings of pulmonary congestion, receiving IV diuretics or vasoactive drugs and having a BNP \> 350 or NT-pro BNP \> 1800 pg/ml.
  3. * Able to give informed consent.
  4. * Participant's residence has adequate cellular data coverage.
  5. * Participants with previous diagnosis of left ventricular ejection fraction (LVEF) \<40% prior to the index hospitalization must have been treated for at least 90 days prior to enrollment with diuretics and beta-blocker (unless intolerant or contraindicated) and an ACE inhibitor or ARB or ARNi (unless intolerant or contraindicated).
  1. * Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)
  2. * Terminal condition with life expectancy less than 6 months as determined by investigator.
  3. * Participants with cardiac tamponade or constrictive pericarditis.
  4. * Participants with left ventricular assistance device (LVAD device) or had a cardiac transplantation or listed for transplantation.
  5. * Implantation of a CRT (cardiac resynchronization therapy) device during index hospitalization or intent to implant a CRT device.
  6. * Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation, as determined by investigator.
  7. * Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis, as determined by investigator.
  8. * Severe primary pulmonary, renal or hepatic disease, as determined by investigator.
  9. * Women of childbearing age (Age \<50).
  10. * History of pulmonary embolism of less than 3 months.
  11. * Dialysis dependent or dialysis initiation expected within three months.
  12. * Chronic home IV therapy or cardiac inotropes or diuretics.
  13. * Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment.
  14. * Illness/ Condition which may be aggravated or cause significant discomfort by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes).
  15. * Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator's assessment.
  16. * Congenital heart malformations (Complex, or uncorrected congenital heart disease).
  17. * Participant enrolled in another interventional study (observational or registries are not excluded).
  18. * Participant HF is managed remotely with another monitoring device or program (for example: Pulmonary/ Lt Atrial pressure monitoring, lung fluid monitoring. BNP/pro-BNP or bioimpedance or ICD or biventricular pacemaker with impedance monitoring will be allowed unless it is part of another research protocol).
  19. * Prisoners and wards of the state.
  20. * Inability to provide informed consent (Must speak English or Spanish or Creole).

Contacts and Locations

Study Contact

Cindy Kober
CONTACT
561-945-9303
cindy@aventusoft.com
Kaustubh Kale
CONTACT
954-399-3335
kaustubh@aventusoft.com

Principal Investigator

David Snipelisky, MD
PRINCIPAL_INVESTIGATOR
Cleveland Clinic Florida

Study Locations (Sites)

Cleveland Clinic Florida
Weston, Florida, 33331
United States
Baylor Scott & White Research Institute
Temple, Texas, 76508
United States

Collaborators and Investigators

Sponsor: Aventusoft, LLC.

  • David Snipelisky, MD, PRINCIPAL_INVESTIGATOR, Cleveland Clinic Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-01-31
Study Completion Date2024-12

Study Record Updates

Study Start Date2022-01-31
Study Completion Date2024-12

Terms related to this study

Additional Relevant MeSH Terms

  • Heart Failure (HF)